Overview

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Status:
Completed
Trial end date:
2018-10-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
Phase:
Phase 3
Details
Lead Sponsor:
Iron Therapeutics
Shield Therapeutics
Treatments:
Ferric Compounds
Ferric maltol